Close Menu

BMS

This article was originally posted March 29.
The annual meeting of the American College of Cardiology held last week in Chicago featured a number of pharmacogenomically guided studies related to treatments for cardiovascular disease.

NEW YORK (GenomeWeb News) – Bristol-Myers Squibb and Meso Scale Discovery today announced a deal to develop assays for use in Alzheimer's disease research.

By Monica Heger

Despite being the third best-selling drug in 2010, as many as one-third of cardiology patients do not respond to Bristol-Myers Squibb's blood-thinning drug Plavix (clopidogrel).

By Adam Bonislawski
Biotech firm KineMed said this week that it has signed a research collaboration agreement with Pfizer to investigate therapies for metabolic diseases, particularly type 2 diabetes.

The headline and this story have been updated to reflect that BMS and Lilly have submitted to the FDA retrospective analysis on Erbitux's efficacy in colorectal cancer patients with wild-type KRAS mutations, which the agency may use to update the drug label.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.